Answers are grounded in this paper and cite their sources.
Expert clinical advice outlines renal replacement therapy selection in end-stage renal disease, highlighting patient education and unbiased modality access.
Creating and updating evidence-based guidelines in medicine are costly and time-consuming. For that reason, the nephrological community tried to build up a single set of international guidelines under the aegis of Kidney Disease Improving Global Outcomes (KDIGO) [1]. However, this international effort may not be correctly perceived by European nephrologists, who sometimes feel that differences in practice patterns make it difficult to apply guidelines developed outside Europe. On the other hand, the latest versions of the European Best Practice Guidelines (EBPG) may appear outdated in some respects, while not all aspects of nephrological practice are currently covered by KDIGO. A specially appointed ERA–EDTA Work Group met in Paris to discuss a European guideline planning in early January 2008, and agreed that the Association should continue producing and updating guidelines in collaboration with KDIGO [2]. It also agreed that ERA–EDTA should issue suggestions for clinical practice in areas in which evidence is lacking or weak, which would be published as ‘clinical advice’ rather than ‘clinical guidelines’ [2]. With regard to peritoneal dialysis (PD), the European Renal Best Practice (ERBP) Advisory Board recently decided not to create new or updated guidelines, as there was not enough new evidence to produce a meaningful change in scope from the previous guidance documents published in 2005 by EBPG [3]. Instead, it was felt that advice on three important PD-related topics for everyday clinical use was needed: peritoneal membrane evaluation, modality selection and adequacy. The text on membrane evaluation is currently in press [4]. The present publication comprises the clinical advice on renal replacement therapy (RRT) modality selection for end-stage renal disease (ESRD) patients. These recommendations have been issued by an ERBP Expert Group and approved by the ERBP Advisory Board. Four areas of interest will be discussed: Initial dialysis modality selection Choice between continuous ambulatory PD (CAPD) and automated PD (APD) Transition between RRT modalities Assisted PD There is insufficient evidence to support a general preference of HD over PD, or vice versa, for medical reasons. Therefore, the initial modality choice should be made primarily by the well-informed patient. As a consequence, all RRT centres should try and provide, or support in collaboration with other centres, all available treatment options: PD (including CAPD and APD), HD (including home HD and nocturnal programmes) and transplantation (including cadaveric and non-cadaveric), to make sure that all patients can select the modality that is most suitable for them. As a consequence, all patients and their families should receive well-balanced information about the different RRT modalities, by means of a structured education programme. This also applies to late-referred patients and those starting dialysis in an emergency situation, which should receive the information once their condition has stabilized. Most studies suggest a better survival rate in PD than in HD patients during the first few years after starting therapy. The only randomized controlled trial on this subject supports this idea [5]. However, after 2 or 3 years, outcome on PD becomes equal to HD, or worse [6–9], depending upon the study. These differences in outcome seem to be attributable to differences in statistical approach, patient mix and experience with the different modalities. Indeed, outcomes on RRT, both in absolute terms and in relative terms (PD vs HD), appear to be strongly influenced by country and centre experience. Based on these findings, the ERBP Expert Group suggests that the ‘PD first’ approach should be presented to the patient as the most logical choice [10]. However, it also feels that there is not enough hard evidence to consider starting with PD as compulsory. Therefore, the patient’s preference should be taken into account as the primary factor, since patient satisfaction, compliance with therapy and quality of life are better if the patient has been given the opportunity to make his/her own informed choice. Actually, in most European Countries and also at EU level, it is compulsory by law to inform patients of all treatment modalities [11,12]. There is now accumulating evidence that the outcome of patients treated in centres where only one modality is available, or where experience with alternative dialysis strategies is limited, is jeopardized [13]. This seems reasonable as it implies that, in those centres, patients are forced to the only available RRT option, or are treated suboptimally by lack of experience. All centres should make sure they provide, or at least support in collaboration with another centre, all available modalities, including home HD. Although, for obvious reasons, no data on randomized controlled trials are available on this topic, some recent well-conceived cohort studies have indicated that outcome of home (daily) HD is superior to conventional in-centre dialysis, and even equal to cadaveric transplantation, when differences in case mix are taken into account [14]. Meanwhile for logistical reasons, it may not be feasible for all centres to develop their own freestanding home HD programme, and it is strongly advised that centres organize such a programme jointly. In such an agreement, care should be taken for a fair distribution of duties and benefits between centres, to avoid eventual economical bias hampering free patient selection for home HD. Also, the option of renal transplantation, both cadaveric and non-cadaveric, should be discussed with the medically suitable patients, as the outcomes of those patients appear to be better after transplantation as compared to standard haemodialysis [15]. However, for the elderly and for patients with multiple co-morbidities, this benefit is less clear [16]. It should also not be neglected that there is shortage of organs, and that it might be preferable, from a socio-ethical viewpoint, to allocate organs to those patients who are expected to benefit the most from kidney transplantation. The following conditions should not be considered as contraindications to PD: Physical or mental inability to perform PD Older age Poor adherence/non-compliance to therapy Obesity Congestive heart failure Polycystic kidney disease Diverticulosis Abdominal hernias Portal hypertension Liver transplantation Performing PD requires a minimum of physical skills and mental capacity. It is clear that some physical problems, such as visual impairment and tremor or deformities of the hands, may interfere with PD handling. In the opinion of the ERBP Expert Group, these problems do not a priori preclude the application of PD as an RRT. Several companies and research groups have invested in the development of tools to ease handling of the PD equipment [17,18], and it is the task of the PD team to provide creative solutions to individual problems. Moreover, several centres in the world have gained experience in the so-called ‘assisted PD’ [19–21]. In this setting, it is not the patient him/herself but a nurse or another assisting person that performs the PD treatment. Assisted PD must be considered as an alternative to in-centre HD for non-autonomous patients. Even with the additional cost of the assistance, assisted PD in developed countries has been reported to be cheaper than in-centre HD [22] (for details, see ‘Assisted PD’ section below). There are an increasing number of elderly patients starting dialysis worldwide. In Europe, in 2008, the population older than 65 years accounted for 17% of the general population [23], and can be expected to continue to grow in the future. When advising elderly patients on modality selection, the following points should be considered [24]. On one hand, elderly patients starting RRT have numerous co-morbidities at dialysis initiation [25]. Older age is frequently associated with loss of physical functions such as strength, dexterity, vision or hearing. Furthermore, elderly patients may present cognitive dysfunction at dialysis start. The initiation of dialysis can be associated with a significant decline in the functional status [26,27], and also cognitive function may deteriorate after dialysis initiation. This implies that assistance may become necessary in self-care patients during the course of their PD treatment. However, caregivers of elderly patients on PD may experience adverse effects on their own quality of life [28], which may, in turn, cause a loss of assistance. On the other hand, PD may present some advantages in the elderly patients with ESRD. Access failure rate is higher in the older HD patients [29]. Elderly patients on dialysis are exposed to arrhythmia and hypotension during the HD sessions. Quality of life is particularly relevant for the elderly patients on dialysis. Travel time to and from the HD centre has a negative impact on patient’s quality of life [30,31], whereas home therapy as offered by PD is associated with a better quality of life compared with in-centre HD. In view of all the above, non-dialytic (or so-called conservative) treatment should also be discussed with the patient and his relatives. A projection of expected survival using the algorithm developed by Couchoud et al. [32] can be of help to visualize the concept and consequences of dialytic versus non-dialytic treatment. The ERBP Expert Group also endorses the active use of advanced care directions, especially in the frail and elderly patients. Presumed or real non-adherence to the prescribed PD regimen can be a challenge to the PD team. Nevertheless, it is unlikely that non-adherent PD patients will become compliant HD patients. It is important for the caregiver, particularly if there is a sudden change in adherence of the patient, to try and find out why this happened. It is especially important to find out whether the non-compliance is related to the PD therapy itself or whether it is a general attitude of the patient. In some cases, the cause of non-compliance is a condition that requires attention from the caregiver, such as denial of disease, depression, social problems (like divorce or death of a beloved person), intercurrent illness and cognitive deterioration. Some of these conditions are only temporary and/or can be treated adequately. Some of the adherence problems may be solved by the implementation of assisted PD [21]. There is currently not enough evidence to contraindicate PD to obese individuals. However, several comments on this issue are necessary. Obese patients, especially if diabetic, were shown to have increased risk of death after starting on PD compared to HD [33,34]; however, such evidence is scarce. Furthermore, most studies in PD patients have found similar (if not better) survival in those who are obese versus those with normal body mass index [35,36]. Obese patients may need larger dialysate volumes, usually provided by APD, to achieve adequate Kt/V, although the increase in body mass is not associated with a proportional increase in body water volume [37–39]. However, PD may not be the preferred dialysis modality or is relatively contraindicated in patients with morbid obesity [39,40], in which there may be difficulties in peritoneal catheter placement and tunnel healing process, increased risk of pericatheter leak and infection, possible further weight gain due to increased caloric absorption from the dialysate, as as a risk for or and of hernias or disease, of increased volume and of may be considered for obese patients as the body weight and mass in studies have been shown to be relative in patients using one of compared to patients using solutions only Congestive heart failure is in patients with ESRD. It is associated with in of and it is one of the of during to weight in HD patients. As PD, with and for might be a better and The only the outcome of patients with on PD vs HD was in the and found a higher risk in PD patients However, to the ERBP Expert Group, the of this be to European patients, of the different case mix and of the and since no was available to help in PD patients. In and even that a bias as it only patients who the first on dialysis, a time bias in of HD. In selection bias not be accounted for in this study. that PD can quality of life and Association in patients with Based on the it is difficult to support or PD as a of choice in patients. however, be that of PD patients with in which adequate weight is Furthermore, be present and significant for the and use of additional for weight (like or is patient of water and to peritoneal and renal function in cases, use of and PD solutions are for the of these patients However, if weight is to patients should be to HD, using The ERBP that this is an important for in view of the increasing of these and the lack of well-conceived trials on this There is as such no to CAPD or APD, as as the time of the patient is to his/her peritoneal As outcomes on both modalities have been found to be choice should be by patient Several studies have that outcomes on CAPD and are However, it is important to the time for the for to avoid absorption and negative and for to avoid [4]. to do might to and It is that can be with the use of a whereas seem to be for As a consequence, it is not to see that outcome of has been reported to be superior on APD, whereas outcome of was better on CAPD It should be however, that, even with can be and the treatment can be with an to achieve PD should try to the patient’s with the membrane using the available their experience and the first of this publication with the choice of RRT modality when a patient the present on from one modality to another once the of RRT has been of should be HD to PD, PD to HD, and renal transplantation to HD or single modality may not adequate treatment over an sometimes have to modalities during the clinical course of patients. the consequences of should be to benefits or not only in the but also in the with kidney disease should be the of their RRT, about the of to an alternative modality on during the course of their RRT. For that reason, there are absolute contraindications for a information provided to patients should all possible as or In the opinion of the ERBP Work Group, the patient’s informed choice of treatment modality should be as as his/her clinical conditions a RRT modality becomes to another therapy should be and the should be to the patient. Even in these the choice of the well-informed patient should be When patients not to medical obvious treatment it should be that the change in treatment has been The be considered as adherence to the modality by the In the ERBP Work Group some conditions where the option of PD should be to the patient as a alternative for HD, as this treatment might be for some on HD should be informed about the option of PD when they from the following clinical and of weight to create a or The for PD in case of of HD or is obvious In to HD, PD is a continuous therapy that is not by volume or sudden in or or nocturnal HD, at may also be in to should the information to the patient on the of for HD, the need for of for placement of and the that starting with PD is a means of the In HD patients, where of a is not PD should be as a better alternative than the use of which are associated with and risk on PD is to that of HD patients with a whereas the risk of a HD catheter is as may be due to heart failure or peritoneal during HD may be to from the body and sometimes the due to it will to do PD may be a better since can be the PD catheter The of loss of or higher risk seem It has been that the outcome of patients from HD is similar to that in patients who are on PD from the of RRT on on PD should be informed about the option of HD when they from the following clinical to or to or to a in renal function is an important of outcome in PD patients is related to dysfunction and on to achieve and in individual PD patients is by the of a and with which to volume lack of in the of and associated with volume in PD can have several which can be even present in the patient at the The most are of and/or and peritoneal with of the is a which can be by a membrane and therapy can be as in the EBPG guidelines on this issue of such as absorption or increased can be by rate of from the peritoneal or Most of or tunnel can be treated with and should not be a to patients to HD. There are some to this general or tunnel to or by with the catheter as failure to clear the peritoneal from after than of and as a new with from the previous catheter in to the problems. Also, catheter is in and in of with or multiple in these requires a of peritoneal of a new catheter at in case of of requires temporary to HD, renal function is or in membrane may be a of and further of it is difficult to their and the ERBP Work Group feels that of a new PD catheter and PD treatment should be considered if the patient to on It should also be in that or be a of peritoneal membrane of PD should be that, in these PD is and that to HD might be some time of a new catheter should be under in to visualize The of renal function as a of PD outcome has been by numerous studies The PD community on this since some of the larger trials on PD to further of outcome by increasing peritoneal The benefits of have been to in the of with and better functions and of and to the of Based on these some have that PD patients should be to HD in case of a loss of however, it is that, also in HD patients, is an important of In several studies have that PD in patients is with outcomes attention has to be however, to the volume status of these patients. the of for should be to by The use of and has been shown to have a impact on can the of the peritoneal to or insufficient However, some or of a renal can be the peritoneal It is to inform the about the of peritoneal membrane and to consider to avoid of the peritoneal Some of PD patients to HD after 2 or 3 years from PD even when of the treatment is This is on the that, after a few years, outcome on PD to worse than on HD [6–9], and on the that PD may become with and/or that the of to with time on The ERBP Expert Group endorses the of the for that time on PD should not be a in itself for patients from PD to HD However, with an increasing on PD, should be of the of the and discuss these and the possible with the patient. In patients with renal transplantation who to dialysis, there is no in survival between HD and Therefore, the choice of dialysis modality for these patients should be on the as those to the initial modality choice. There is data available on the impact of dialysis modality on the outcome of patients with kidney However, PD seems to be in this setting, for several in most dialysis centres, HD is over the of dialysis in emergency also the of increased rate or of loss of in patients to PD et al. reported higher and in patients starting PD after failure compared to PD patients. On the other hand, that there is no significant in survival between these of PD patients after for age and Furthermore, other studies found similar of renal and peritoneal decline and failure in both and PD however, studies are and in found no differences in survival of patients with renal transplantation on HD versus PD The issue of or not after PD is a of since there is no evidence of the effects of function to On the other hand, the of therapy implies an increased risk of and Therefore, the is currently on of is preferable, as it was shown to be associated with similar after on PD as in patients, increasing the risk of Assisted PD can be as a PD modality at the patient’s home with the assistance of a a community a or a is necessary when patients are assisted by a nurse or by a Therefore, when using the ‘assisted information the of assistance must be There are modalities of assisted PD: assisted and assisted Assisted PD must be considered as an alternative to in-centre HD for non-autonomous patients. Even with the additional cost of the assistance, assisted PD in developed countries is reported to be cheaper than in-centre HD although may between Assisted PD to increase the use of PD in dialysis patients must be by from the PD centre to perform the and the and to set up the in case of assisted A to provide medical or to those in the patient’s care is The PD centre must with the patient in the PD and in the necessary. For assisted APD, only at the patient’s home are necessary whereas patients on assisted CAPD need In countries where assisted PD is covered by the most of the patients on assisted PD are treated by assisted CAPD cognitive dysfunction and/or to the therapy may this In to the time by at the patient’s a with can be on assisted PD must be to see whether or not they have become to perform self-care For patients on assisted APD, assistance is associated with a compared with nurse assistance However, the are when centres one of their PD for a at the patient’s home on a this the that in of assisted PD patients must be and by the from the PD In elderly patients, assisted CAPD is not associated with risk compared with the CAPD or PD is indicated for patients who PD as RRT modality or in HD is who have no to PD, but are to perform PD by and quality of life is by the of Assisted PD can be indicated in dialysis patients or in self-care PD patients who have their The dialysis can be as a patient who dialysis or PD These patients usually HD a strategies to use PD for dialysis were Assisted PD can be for a of time patient education and are of the ERBP Advisory Board. of the ERBP Advisory Board are and This has been approved by the Advisory Board of ERBP and by the ERA–EDTA as as by an The to and for their The present text is upon the information available to the at the of the of this It has been to provide information and but is not to a standard of care or to an course of or treatment. is in the approach to in practice are when into account individual patient available and for a or of In evidence may change over time as new information becomes available, that practice may be using this text is for application to clinical The in the development of the present text have all and of interest that may as a of an outside or a or The presented in this have not been published in or of interest from and and from research support from and is a for research from and and have no of interest
No takes yet. Share an insight, caveat, or question.
Covic et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: